Form 4: Kura Oncology Chief Legal Officer Sells Shares to Cover Taxes

Kura Oncology's Chief Legal Officer, Teresa Bair, sold shares to cover taxes related to the vesting of restricted stock units.

Summary

• Teresa Bair, the Chief Legal Officer of Kura Oncology, sold a total of 7,281 shares of common stock on January 28, 2025.
• The sales were executed at a price of $7.8719 per share.
• These transactions were made to cover tax obligations arising from the vesting of restricted stock units (RSUs).
• The first sale of 2,437 shares was related to RSUs granted on February 16, 2023.
• The second sale of 4,844 shares was related to RSUs granted on January 2, 2024.
• Following these transactions, Ms. Bair directly owns 107,948 shares of Kura Oncology stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when RSUs vest.

Comparison to Industry Standards

• Similar transactions are common across the biotechnology industry, where stock-based compensation is a significant part of executive pay.
• Many executives at comparable companies such as Amgen, Gilead, and Regeneron regularly sell shares to cover taxes related to vesting RSUs.
• The volume and price of the shares sold are not unusual for a company of Kura Oncology's size and stage.

Stakeholder Impact

• The stock sales by the Chief Legal Officer may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small volume of shares sold.
• The transaction is not expected to have any material impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Kura Oncology, insider trading, stock sale, Teresa Bair, restricted stock units, tax obligations, Form 4, Chief Legal Officer